Various investigations can be used to help diagnose tuberculosis. These include medical imaging, microbiology tests, tests of a patient's immune response (tuberculin skin testing and interferon gamma release assays) and histopathology.
Chest radiology
If a patient has no respiratory symptoms, a normal chest X-ray almost excludes pulmonary tuberculosis. Chest X-rays are valuable for detecting pulmonary lesions of tuberculosis, however activity of disease cannot be judged with certainty.
Table 1
|
Risk factors for tuberculosis in Australia
|
|
Increased risk*of tuberculosis infection (i.e. increased risk of exposure to infectious tuberculosis)
|
Migrants from high tuberculosis prevalence countries Members of Aboriginal and Torres Strait Islander communities with high incidence of tuberculosis
Healthcare workers
Household contacts (particularly children) of people at increased risk for tuberculosis
|
Increased risk†of tuberculosis developing after infection‡
|
HIV infection
Silicosis
Diabetes mellitus
Chronic renal failure/haemodialysis
Gastrectomy/jejunoileal bypass surgery
Organ transplantation requiring immunosuppression
Carcinoma (particularly head and neck carcinoma)
Immunosuppressive therapies (corticosteroids, cytotoxic chemotherapy, tumour necrosis factor alpha inhibitors)
Malnutrition and low body weight (≥10% less than ideal)
Infancy
Older age
|
|
* In other countries, residents of institutions (prisons, nursing homes), homeless people, users of illicit intravenous and other drugs (especially when associated with HIV infection), and impoverished populations with limited access to medical services have high incidence of tuberculosis infection. In general, the risk for these populations has not been as great in Australia with the exception of Aboriginal and Torres Strait Islander populations.
† Most of this risk is related to cellular (T lymphocyte) immune defects.
‡ Patients with infections acquired within one year or with chest X-ray findings of fibrotic lung lesions consistent with untreated inactive tuberculosis have much greater risk of tuberculosis than those with tuberculosis infection acquired more than seven years previously.
|
Fig. 1
|
|
Natural history of tuberculosis in newly infected contacts
|
|
|
Classic upper zone chest X-ray changes (Fig. 2) can be due to other pathology, and pulmonary tuberculosis can have many other non-classic presentations with broad differential diagnoses. Unusual chest X-ray presentations (including normal chest X-ray) are more common in people with immune deficiencies and other comorbidities. Once pulmonary tuberculosis is suspected, the most appropriate initial investigation is sputum analysis and not further imaging, even if chest X-ray shows fibrosis which appears to be radiologically inactive.
Culture
Identifying M. tuberculosis remains the definitive means for diagnosis of active tuberculosis. Although culture of M. tuberculosis from a specimen is a sensitive test (75–80%), bacteria can take up to six weeks or more to grow. Collection of specimens should include three morning sputa whatever the suspected site of disease, unless chest X-ray is normal and there are no respiratory symptoms in a person with localised extrapulmonary disease.
Fig. 2
|
Chest X-ray showing pulmonary tuberculosis
|
|
Chest X-ray of an 18-year-old female who was part of a cluster of cases involving indigenous people in south-east Queensland and northern New South Wales. She presented with a history of cough for six months followed by weight loss, fevers, night sweats and fatigue. Sputum was smear-positive for acid-fast bacilli and grew M. tuberculosis.The X-ray shows an extensive infiltrate in the upper lobe of the right lung with air-space consolidation (note air bronchogram ) and the formation of a number of cavities (+).There are surrounding reticulonodular satellite lesions and fibrosis of the involved lung with traction of the right upper hilum.
|
Smear microscopy and nucleic acid amplification
Mycobacteria retain certain dyes after being treated with acid and are classified as acid-fast bacilli. After collection, specimens can therefore be smeared on a slide, stained and visualised under the microscope. Although this technique, along with nucleic acid amplification, allows early identification it fails to detect many culture-positive cases. Nevertheless, microscopy for acid-fast bacilli rapidly identifies the most infectious tuberculosis cases and a positive sputum smear is sufficient for provisional diagnosis of tuberculosis.
When smears are positive for acid-fast bacilli, nucleic acid amplification of M. tuberculosis DNA can be used to rule out nontuberculous mycobacteriosis. This test has almost 100% specificity and sensitivity in acid-fast bacilli positive smears, with results provided within a few days (and potentially on the same day).While a negative nucleic acid amplification test of acid-fast bacilli almost excludes tuberculosis, the test can rarely be falsely negative in pulmonary tuberculosis (Fig. 3). Sputum smear-positive pulmonary tuberculosis is infectious so it is important to maintain infection control procedures while awaiting culture confirmation regardless of the nucleic acid amplification test result.
Screening for latent tuberculosis infection
The Australian National Tuberculosis Advisory Committee recommends tuberculin skin testing as the standard test for latent tuberculosis infection with targeted use of interferon gamma release assays (Quantiferon Gold) when high specificity is desired.
These tests have no role in initial investigations for active tuberculosis because negative results do not exclude disease and positive results may not necessarily indicate disease.
Tuberculin skin testing1,2
This test measures a patient's immune response to M. tuberculosis antigens (tuberculin). A small amount of tuberculin is injected intradermally and the skin reaction is measured two or three days later (Fig. 4).
The test is very sensitive for detecting tuberculosis in healthy individuals if 5 mm induration is used to define a positive reaction. However, many conditions result in false negative reactions, including active tuberculosis (Box 1, part A). Bacillus Calmette-Gurin (BCG) vaccination and exposure to environmental nontuberculous mycobacteriosis cause intermediate size reactions (Box 1, part B). Sensitivity is often sacrificed by choosing larger indurations to define a positive reaction based on the incidence of tuberculosis and the extent of non-specific cross-reactivity in the population being tested. Box 2 provides general recommendations for categorising skin reactions, but regional tuberculosis control units should be consulted for local guidelines.
Chest X-ray showing examples of sputum smear-positive tuberculosis with negative nucleic acid amplification test
Fig. 3
|
|
|
|
|
A. Chest X-ray of 51-year-old male who arrived in Australia 15 years earlier from Vietnam. The X-ray was taken for investigation of unrelated shoulder pain and shows a cavity (+) adjacent to the left hilum. Sputum was smear-positive for acid-fast bacilli, however nucleic acid amplification was negative for M. tuberculosis.This was presumably because the organism lacked the IS6110 DNA insert which was the target of the test.
|
B. Routine chest X-ray taken for visa purposes in a 28-year-old university student from India. The X-ray showed a small cavity (+) with some surrounding infiltrate () adjacent to the left upper hilum. Initial sputum samples collected were smear-positive for acid-fast bacilli, but were repeatedly negative by nucleic acid amplification testing. Sputum samples were subsequently repeated. These specimens were more heavily smear-positive and tested positive for M. tuberculosisby nucleic acid amplification. The negative results were most likely due to a sampling error during collection of the first sputum specimen.
|
|
Tuberculin skin testing, Mantoux method
Fig. 4
|
|
|
|
|
A. Intradermal injection of tuberculin
|
B. Measuring induration 72 hrs later. Note: only the diameter of induration should be read, not the diameter of erythema.
|
|
Box 1
|
Factors that influence interpretation of tuberculin skin tests
|
|
A. Factors that may decrease skin reaction or give false negative reactions
|
Infections
Viral (e.g. HIV infection, measles, mumps, chickenpox) Bacterial (e.g. pertussis, brucellosis, leprosy, overwhelming tuberculosis, pleural tuberculosis) Fungal
Live virus vaccination (e.g. measles, mumps, polio)
Metabolic disease (e.g. chronic renal failure)
Malnutrition/protein depletion
Lymphoid neoplasms (e.g. Hodgkin's disease, lymphoma, chronic lymphocytic leukaemia)
Sarcoidosis
Drugs (corticosteroids, immunosuppressants)
Age (newborns and elderly)
Tuberculosis infection acquired within last eight weeks
Other conditions causing cell-mediated immune suppression
Local skin damage (dermatitis, trauma, surgery)
Incorrect handling and storage of tuberculin
Poor technique (related to intradermal injection or measuring induration)
|
B. Factors that may increase skin reaction or give false positive reactions
|
Exposure to or infection with nontuberculous mycobacteria
Past BCG vaccination
Trauma and irritation to site of intradermal injection before reading
Poor technique
|
|
BCG Bacillus Calmette-Guérin vaccination
|
|
Box 2
|
Criteria for defining a tuberculin skin testing reaction as positive *
|
|
≥5 mm – in people with recent exposure (within 2 years) to tuberculosis + high risk for progression to active disease (e.g. <5 years of age, HIV infection, other immunosuppressive illness; see Table 1)
≥10 mm – in people with recent exposure to tuberculosis, regardless of BCG vaccination status; all non-BCG vaccinated people except for those with both low lifetime risk for tuberculosis infection and residence in geographical areas where exposure to environmental nontuberculous mycobacteriosis is common
≥15 mm – in all people regardless of BCG vaccination status
|
|
*
|
This refers to the induration produced by an intradermal injection of purified protein derivative (PPD) equivalent to 5 units of PPD-S. These criteria are meant as suggestions only. Local tuberculosis control units should be consulted for local guidelines.
|
BCG Bacillus Calmette-Guérin vaccination
|
|
As skin test reactivity can wane with time, two-step skin testing is sometimes used. If the initial skin test is not positive, it can be repeated within one or two weeks (to minimise the possibility of new tuberculosis infection influencing the re-test result) when antigen from the first test would have stimulated recruitment of memory T cells to the area. This will also boost non-specific reactivity from BCG and nontuberculous mycobacteriosis. It is used either to detect infections from the distant past, for example in older people being screened before starting immunosuppressive therapy, or to establish a baseline when repeat testing is planned to monitor for new tuberculosis infection.
Interferon gamma release assays
The non-specificity of tuberculin skin testing (Box 1) and the dependence on well-trained staff to minimise human error are overcome by interferon gamma release assays. These laboratory tests are much more specific than tuberculin skin testing3-6 because the antigens used are expressed by M. tuberculosis, but not BCG or most nontuberculous mycobacteriosis (exceptions include M. kansasii, M. marinum, M. szulgai and M. flavescens).The current blood tests either measure the amount of interferon gamma released by lymphocytes or quantify the number of T lymphocytes releasing interferon, after incubation with M. tuberculosis antigens.
Interferon gamma release assays are at least as sensitive as tuberculin skin testing for detecting recently acquired latent tuberculosis infections and may be even more sensitive for detecting recently acquired active infections.5 Their increased specificity makes them useful in screening for recent tuberculosis infection in populations with a low incidence of tuberculosis and high uptake of the BCG vaccination. However, many studies show that tuberculin skin testing and interferon gamma release assays perform similarly in non-BCG vaccinated people at high risk for recent tuberculosis infection, if an appropriate cut-off (for example 10 mm induration) is used for tuberculin skin testing.5
It is not known if interferon gamma release assays are as sensitive as tuberculin skin testing for detecting remotely acquired (more than 5–10 years earlier) latent infections which may reactivate during immunosuppressive therapy. It is also suggested that interferon gamma release assays may be inferior to tuberculin skin testing in young children, particularly those under two years.3
Tuberculin skin testing does not require access to laboratory or phlebotomy so it is useful in remote settings and for infants and children. With well-trained staff, skin testing can be combined with counselling, education and clinical assessment for active tuberculosis. The distribution of tuberculin skin testing reactions in various populations 1, 2 Is better understood than that of interferon gamma release assays. Performance of interferon gamma release assays has not been tested in geographical areas where subclinical infections due to nontuberculous mycobacteriosis such as M. marinum or M. leprae are common.
Histopathology
Pathological examination of biopsied tissue may support a diagnosis of tuberculosis when bacteriology is negative or cannot be done, however histology is non-specific. Always ensure enough tissue is available for culture if it is required.
The patient's risk of tuberculosis should be considered to avoid misclassifying non-caseating granulomatous processes due to tuberculosis as sarcoidosis, Crohn's disease, or other granulomatous disease. Similarly, caseating granulomas due to tuberculosis in cervical lymph nodes of young children may be misclassified as nontuberculous mycobacterial lymphadenitis.